Mesoblast Stock Revenue
| MESO Stock | USD 13.19 0.36 2.66% |
Mesoblast fundamentals help investors to digest information that contributes to Mesoblast's financial success or failures. It also enables traders to predict the movement of Mesoblast Stock. The fundamental analysis module provides a way to measure Mesoblast's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mesoblast stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 6.8 M | 6.4 M |
Mesoblast | Revenue |
Mesoblast Company Revenue Analysis
Mesoblast's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Mesoblast Revenue | 5.9 M |
Most of Mesoblast's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesoblast is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Mesoblast
Projected quarterly revenue analysis of Mesoblast provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Mesoblast match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Mesoblast's stock price.
Mesoblast Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Mesoblast is extremely important. It helps to project a fair market value of Mesoblast Stock properly, considering its historical fundamentals such as Revenue. Since Mesoblast's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mesoblast's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mesoblast's interrelated accounts and indicators.
| 0.34 | -0.8 | 0.09 | 0.35 | 0.26 | ||
| 0.34 | -0.34 | -0.14 | 1.0 | 0.61 | ||
| -0.8 | -0.34 | -0.13 | -0.37 | -0.13 | ||
| 0.09 | -0.14 | -0.13 | -0.11 | 0.22 | ||
| 0.35 | 1.0 | -0.37 | -0.11 | 0.61 | ||
| 0.26 | 0.61 | -0.13 | 0.22 | 0.61 |
Click cells to compare fundamentals
Mesoblast Revenue Historical Pattern
Today, most investors in Mesoblast Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mesoblast's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Mesoblast revenue as a starting point in their analysis.
Mesoblast Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Mesoblast Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Mesoblast reported 5.9 M of revenue. This is 99.92% lower than that of the Biotechnology sector and 99.21% lower than that of the Health Care industry. The revenue for all United States stocks is 99.94% higher than that of the company.
Mesoblast Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in revenue category among its peers.
Mesoblast Current Valuation Drivers
We derive many important indicators used in calculating different scores of Mesoblast from analyzing Mesoblast's financial statements. These drivers represent accounts that assess Mesoblast's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mesoblast's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 852.9M | 259.0M | 531.2M | 657.9M | 756.6M | 1.3B | |
| Enterprise Value | 821.5M | 305.8M | 576.8M | 714.3M | 821.4M | 1.2B |
Mesoblast ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mesoblast's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mesoblast's managers, analysts, and investors.Environmental | Governance | Social |
Mesoblast Institutional Holders
Institutional Holdings refers to the ownership stake in Mesoblast that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mesoblast's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mesoblast's value.| Shares | Rockbridge Investment Management, Llc | 2024-12-31 | 49.1 K | Oaktree Fund Advisors, Llc | 2024-12-31 | 47.9 K | Lpl Financial Corp | 2024-12-31 | 38.9 K | Cubist Systematic Strategies, Llc | 2024-12-31 | 35.2 K | Creative Planning Inc | 2024-12-31 | 24.9 K | Pine Valley Investments Ltd Liability Co | 2024-12-31 | 20.9 K | Geode Capital Management, Llc | 2024-12-31 | 18.2 K | Thoroughbred Financial Services, Llc | 2024-12-31 | 17.1 K | Wells Fargo & Co | 2024-12-31 | 15.2 K | Blackrock Inc | 2024-12-31 | 727.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 402.4 K |
Mesoblast Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 1.74 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 1.38 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 3.73 X | ||||
| Price To Sales | 303.50 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | (47.42 M) | ||||
| EBITDA | (56.08 M) | ||||
| Net Income | (87.96 M) | ||||
| Cash And Equivalents | 85.5 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 118.92 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (48.46 M) | ||||
| Short Ratio | 6.69 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 73 | ||||
| Beta | 2.34 | ||||
| Market Capitalization | 1.14 B | ||||
| Total Asset | 669.15 M | ||||
| Retained Earnings | (908.76 M) | ||||
| Working Capital | 13.22 M | ||||
| Current Asset | 88.82 M | ||||
| Current Liabilities | 29.41 M | ||||
| Net Asset | 669.15 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock: Check out Mesoblast Piotroski F Score and Mesoblast Altman Z Score analysis. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.